AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced Friday that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in Immunology, with Humira®, and recently launched Skyrizi ™ and Rinvoq™, and Hematologic Oncology, with Imbruvica® and Venclexta®. Allergan provides new growth opportunities in Neuroscience, with Botox® Therapeutics, Vraylar® and Ubrelvy™ and a global aesthetics business, with leading brands including Botox® and Juvederm®. This diversified on-market portfolio will drive the existing AbbVie growth platform (ex-Humira) to approximately $30 billion in revenues in full year 2020, with combined revenues of approximately $50 billion.
Read the full article: AbbVie Completes Transformative Acquisition of Allergan //
Source: https://www.prnewswire.com/news-releases/abbvie-completes-transformative-acquisition-of-allergan-301055950.html